EBR Systems Inc
Research EBR Systems Inc (EBR) on Bullrun: market cap AUD 188.34M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEBR
- ExchangeAU
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyAUD
- Market capAUD 188.34M
- Financial periodQ2 2026
- RevenueUSD 2.64M
- Net income-USD 17.45M
- Gross margin12.9%
Valuation Snapshot
latest market cap is AUD 188.34M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 1.62M | -USD 48.76M | -USD 56.88M | 30.2% | -0.12 | USD 5.79M | USD 58.59M | USD 25.59M |
| FY2024 | n/a | -USD 40.80M | n/a | n/a | -0.13 | USD 6.92M | USD 41.40M | USD 24.36M |
| FY2023 | n/a | -USD 35.04M | n/a | n/a | -0.12 | USD 14.58M | n/a | n/a |
| FY2022 | n/a | -USD 33.09M | n/a | n/a | -0.12 | USD 15.46M | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-06 | AUD 188.34M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About EBR Systems Inc
EBR Systems, Inc. develops implantable systems for wireless tissue stimulation. It offers WiSE cardiac resynchronization therapy system, an implantable cardiac pacing system able to provide stimulation to endocardial heart tissue for the correction of heart rhythm conditions without requiring the use of leads; and stimulation of the left ventricular endocardium for cardiac resynchronization therapy (SOLVE-CRT), an investigational device exemption.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is EBR Systems Inc's market cap?
EBR Systems Inc's market capitalization is AUD 188.34M.
What does EBR Systems Inc do?
EBR Systems, Inc. develops implantable systems for wireless tissue stimulation. It offers WiSE cardiac resynchronization therapy system, an implantable cardiac pacing system able to provide stimulation to endocardial heart tissue for the correction of heart rhythm conditions without requiring the use of leads; and stimulation of the left ventricular endocardium for cardiac resynchronization therapy (SOLVE-CRT), an investigational device exemption. The company was incorporated in 2003 and is headquartered in Sunnyvale, California.